Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. Show more
Location: 2749 East Parleys Way, Salt Lake City, UT, 84109, United States | Website: https://www.sera.com | Industry: Medical Devices | Sector: Healthcare
Market Cap
129.4M
52 Wk Range
$1.37 - $9.13
Previous Close
$3.40
Open
$3.39
Volume
48,291
Day Range
$3.30 - $3.55
Enterprise Value
91.12M
Cash
40.16M
Avg Qtr Burn
-6.57M
Insider Ownership
10.84%
Institutional Own.
64.98%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|